Durvalumab plus chemotherapy
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Small Cell Lung Carcinoma Extensive Disease
Conditions
Small Cell Lung Carcinoma Extensive Disease
Trial Timeline
Dec 7, 2020 → Mar 30, 2023
NCT ID
NCT04449861About Durvalumab plus chemotherapy
Durvalumab plus chemotherapy is a phase 3 stage product being developed by AstraZeneca for Small Cell Lung Carcinoma Extensive Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04449861. Target conditions include Small Cell Lung Carcinoma Extensive Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04449861 | Phase 3 | Completed |
Competing Products
20 competing products in Small Cell Lung Carcinoma Extensive Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 77 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| Pemetrexed | Eli Lilly | Pre-clinical | 23 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 52 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 33 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 69 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 44 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 69 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 52 |
| Cetuximab | Eli Lilly | Phase 1 | 33 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 77 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 52 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 77 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 41 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |